Last-Hope leukemia drug made available through special access program
NCT ID NCT04360005
Summary
This program provides access to the drug asciminib (ABL001) for patients with chronic myeloid leukemia who have run out of standard treatment options. It's designed for people who cannot join regular clinical trials and have no satisfactory alternative therapies available. The program allows doctors to request the drug for eligible patients with serious disease when potential benefits outweigh the risks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.